ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF

• US 20190256604A1
• Filed: 05/08/2019
• Published: 08/22/2019
• Est. Priority Date: 10/27/2017
• Status: Active Grant

• Current Assignee: New York University, Puretech Health LLC (PureTech Health Plc)
• Original Assignee: New York University, Puretech Health LLC (PureTech Health Plc)
• Inventors: Koide, Shohei, Miller, George, Koide, Akiko, Chen, Linxiao, Elenko, Eric, Filipovic, Aleksandra, Bolen, Joseph
• Granted Patent: US 10,450,374 B2
• Time in Patent Office: Days
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 16/065 Purification, fragmentation
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]

Abstract

Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.

Claims

1. A method for inhibiting the activity of galectin-9 or reducing cells expressing galactin-9 in a subject, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an isolated antibody, which binds human galactin-9, wherein the antibody comprises a heavy chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:

361, a heavy chain complementary determining region 2 (CDR2) set forth as SEQ ID NO;

388, and a heavy chain complementary determining region 3 (CDR3) set forth as SEQ ID NO;

406 and/or comprises a light chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO;

328, a light chain complementary determining region 2 (CDR2) set forth as SEQ ID NO;

329, and a light chain complementary determining region 3 (CDR3) set forth as SEQ ID NO;

352.

2. The method of claim 1, wherein the antibody is a full-length antibody or an antigen-binding fragment thereof.

3. The method of claim 1, wherein the antibody is single chain variable fragment or an IgG molecule.

4. The method of claim 3, wherein the antibody is an IgG1 or an IgG4 antibody.

5. The method of claim 1, wherein the antibody comprises a VH set forth as SEQ ID NO:

55 and/or a VL set forth as SEQ ID NO;

54.

6. The method of claim 1, wherein the antibody comprises a heavy chain constant region set forth as SEQ ID NO:

422, and/or a light chain constant region set forth as SEQ ID NO;

418.

7. The method of claim 1, wherein the subject is a human patient, and wherein the human patient has, is suspected of having, or is at risk for a solid tumor.

8. The method of claim 7, wherein the solid tumor is selected from glioblastoma, glioma, melanoma, skin squamous cell carcinoma, sarcoma, upper and lower gastrointestinal cancers, carcinoid tumors, neuroendocrine tumors, breast cancers, lung cancers, head and neck cancers, and genitourinary cancers.

9. The method of claim 1, wherein the method further comprises administering to the subject an effective amount of a checkpoint inhibitor.

10. The method of claim 9, wherein the checkpoint inhibitor is an anti-PD-1 antibody.

11. A method for treating a solid tumor, comprising administering to a human subject in need thereof an effective amount of a pharmaceutical composition comprising an antibody, wherein the antibody comprises a heavy chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:

361, a heavy chain complementary determining region 2 (CDR2) set forth as SEQ ID NO;

388, and a heavy chain complementary determining region 3 (CDR3) set forth as SEQ ID NO;

406 and/or comprises a light chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO;

328, a light chain complementary determining region 2 (CDR2) set forth as SEQ ID NO;

329, and a light chain complementary determining region 3 (CDR3) set forth as SEQ ID NO;

352.

12. The method of claim 11, wherein the antibody is a full-length antibody or an antigen-binding fragment thereof.

13. The method of claim 11, wherein the antibody is single chain variable fragment or an IgG molecule.

14. The method of claim 13, wherein the antibody is a IgG1 or an IgG4 antibody.

15. The method of claim 11, wherein the antibody comprises a VH set forth as SEQ ID NO:

55 and/or a VL set forth as SEQ ID NO;

54.

16. The method of claim 11, wherein the antibody comprises a heavy chain constant region set forth as SEQ ID NO:

422, and/or a light chain constant region set forth as SEQ ID NO;

418.

17. The method of claim 16, wherein the solid tumor is selected from the group comprising glioblastoma, glioma, melanoma, skin squamous cell carcinoma, sarcoma, upper and lower gastrointestinal cancers, carcinoid tumors, neuroendocrine tumors, breast cancers, lung cancers, head and neck cancers, and genitourinary cancers.

18. The method of claim 17, wherein the upper and lower intestinal disorders are selected from the group comprising esophageal cancer, gastric cancer, pancreatic cancer, colorectal cancer, biliary tract cancers, cholangiocarcinoma, gall bladder cancer, liver cancer, and duodenal cancer.

19. The method of claim 11, wherein the method further comprises administering to the human subject an effective amount of a checkpoint inhibitor.

20. The method of claim 19, wherein the checkpoint inhibitor is an anti-PD-1 antibody.